CXCR4 and renal carcinoma: Moreover, targeting the CXCR4–CXCL12–CXCR7 pathway with antagonists (AMD3100 or Peptide R and anti-CXCR7) reinduced RAD001 sensitivity in SN12C- and A498-RAD001-resistant renal cancer cells.